Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.36 |
| ▸ | PADI4 | Q9UM07 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083044 | 1.00 | CHEK1 (0.37) | CHEK1MAPK14LMNAGAAYEATS4 | |
| SCHEMBL3250083 | 1.00 | CHEK1 (0.37) | CHEK1MAPK14LMNAGAAYEATS4 | |
| SCHEMBL3253614 | 0.94 | CDK4 (0.39) | MAPK14SPRHDAC4HDAC1HDAC6 | |
| SCHEMBL4083448 | 0.94 | CDK4 (0.39) | MAPK14SPRHDAC4HDAC1HDAC6 | |
| SCHEMBL3247320 | 0.94 | CDK4 (0.39) | MAPK14SPRHDAC4HDAC1HDAC6 | |
| SCHEMBL19775144 | 0.90 | MAPK14 (0.37) | MAPK14LMNAGAAYEATS4MEN1 | |
| SCHEMBL4094743 | 0.90 | HDAC4 (0.39) | MAPK14LMNAGAAYEATS4MEN1 | |
| SCHEMBL11355346 | 0.90 | POLB (0.42) | MAPK14LMNAGAAMEN1KMT2A | |
| SCHEMBL8096953 | 0.90 | POLB (0.42) | MAPK14LMNAGAAMEN1KMT2A | |
| SCHEMBL3247228 | 0.90 | HDAC4 (0.39) | MAPK14LMNAGAAYEATS4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3311813-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-08-07 | — | — | EP | disclosed |
| EP-3311813-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-08-07 | — | — | EP | disclosed |
| US-10053467-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-21 | — | — | US | disclosed |
| EP-3311813-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Dart Neuroscience (Cayman) Ltd (KY) | 2018-04-25 | — | — | EP | disclosed |
| EP-3311813-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Dart Neuroscience (Cayman) Ltd (KY) | 2018-04-25 | — | — | EP | disclosed |
| EP-2182809-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2018-01-17 | — | — | EP | disclosed |
| EP-2182809-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2018-01-17 | — | — | EP | disclosed |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-20 | — | — | US | disclosed |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-20 | — | — | US | disclosed |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-20 | — | — | US | disclosed |
| US-20120202786-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2012-08-09 | — | — | US | disclosed |
| US-8222243-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2012-07-17 | — | — | US | disclosed |
| US-8222243-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2012-07-17 | — | — | US | disclosed |
| US-8222243-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2012-07-17 | — | — | US | disclosed |
| EP-2182809-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009029632-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009029632-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053467-B2 | Therapeutic isoxazole compounds | MAOB, MAOA, XDH | CHEK1 4453/4885MAPK14 3286/4885LMNA 1890/4885 |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | CHEK1 4453/4885MAPK14 3286/4885LMNA 1890/4885 |
| US-20120202786-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | CHEK1 4453/4885MAPK14 3286/4885LMNA 1890/4885 |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | CHEK1 4453/4885MAPK14 3286/4885LMNA 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.